Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
travoprost + timolol + brinzolamide + brimonidine
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
A combination of four medications used as maximal medical therapy (MMT) for glaucoma and ocular hypertension. This approach involves using two separate fixed-dose combinations together: travoprost 0.004%/timolol 0.5% (TTFC) and brinzolamide 1%/brimonidine 0.2% (BBFC). The combination provides significant intraocular pressure (IOP) reduction through multiple mechanisms of action.
02
Targets
CA2 (Carbonic Anhydrase 2)PTGFR (Prostaglandin F2 alpha receptor)ADRA2A (α2A)ADRB1 (β1)CA (Carbonic anhydrase)
Beyond the preview
Go deeper on travoprost + timolol + brinzolamide + brimonidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on travoprost + timolol + brinzolamide + brimonidine.